In the long search for answers to one of medicine's most unforgiving cancers, researchers at the University of Pennsylvania have found an unlikely candidate in a seventy-year-old blood pressure pill that costs less than a cup of coffee. Hydralazine, already trusted by millions to quiet their arteries, appears to disrupt the very survival mechanism that allows glioblastoma to thrive in the oxygen-starved terrain it creates for itself. The discovery is still confined to the laboratory, but in a disease where half of patients are gone within fourteen months, even a whisper of a new path carries t
Daily Mail Online
· Nov 17, 2025
· health
· 3 min de lectura
Medium
Verificación: Caracterizado
Cheap blood pressure drug shows promise against deadly brain cancer in early study
Glioblastoma affects approximately 12,000 people annually in the US with only 5% five-year survival rate and 50% mortality within 14 months of diagnosis.
◉
Health & Medicine
8412 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% coincidencia
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% coincidencia
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% coincidencia
Cobertura Relacionada
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Sesgo y Encuadre
⚖
Article presents early-stage research optimistically with emphasis on drug's low cost and age, using hopeful framing while acknowledging limited evidence.
Bias Direction
center-right
Confidence
MED
Positive sensationalism with cost-benefit emphasis. The article leads with 'promise' and 'hope' while burying the 'very early stages' caveat. Emphasis on the drug's cheapness ($0.33) and age (70 years old) creates a 'miracle cure' narrative appealing to cost-conscious readers.
deadly brain cancer
one of the deadliest
kills half of patients
potential sign of hope
unusual links that could spell new solutions
teaching us something new
Oncologist skepticism about translating lab results to human trials
Historical context of failed early-stage cancer drug discoveries
Patient advocacy group perspectives on realistic timelines
Pharmaceutical industry commentary on drug repurposing economics
Competing or alternative glioblastoma research approaches
Limitations of in vitro lab testing for brain cancer treatments
Impacto Geopolítico
🌎
Medical research discovery has no direct geopolitical implications; this is a domestic healthcare/scientific advancement with potential global humanitarian benefits.
Escalation Risk
low
Confidence
HIGH
No power dynamics shifts. This is a scientific advancement that could benefit all nations equally if validated and scaled.
Lente Económico
📈
Early-stage research suggests repurposing a 70-year-old $0.33 blood pressure drug (hydralazine) may combat glioblastoma, potentially creating low-cost treatment options but requiring extensive clinical validation before market impact.
Market Signal
mixed
Confidence
LOW
Pharmaceutical manufacturing
Oncology/cancer treatment
Healthcare services
Medical research and development
Generic drug production
Potential long-term benefit for glioblastoma patients through affordable repurposed medication, but immediate consumer impact is minimal as research is in early stages. Could reduce treatment costs if clinical trials succeed, benefiting patients and reducing healthcare expenditures.
May incentivize FDA fast-track approval pathways for drug repurposing. Could influence pharmaceutical pricing policies and R&D incentives for generic drug applications. May prompt increased funding for translational research linking existing medications to new disease indications.